Publicaciones en colaboración con investigadoras/es de Clínica Universitaria de Navarra (21)

2024

  1. Mediterranean diet-based intervention to improve depressive symptoms: analysis of the PREDIDEP randomized trial

    Nutritional Neuroscience, Vol. 27, Núm. 9, pp. 951-961

2023

  1. Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry

    Journal of Headache and Pain, Vol. 24, Núm. 1

  2. ‘Effectiveness of a remote nutritional intervention to increase the adherence to the Mediterranean diet among recovered depression patients’

    Nutritional Neuroscience, Vol. 26, Núm. 8, pp. 696-705

2022

  1. Dysautonomia in COVID-19 Patients: A Narrative Review on Clinical Course, Diagnostic and Therapeutic Strategies

    Frontiers in Neurology, Vol. 13

2019

  1. Preventing the recurrence of depression with a Mediterranean diet supplemented with extra-virgin olive oil. the PREDI-DEP trial: Study protocol

    BMC Psychiatry, Vol. 19, Núm. 1

  2. Small fiber neuropathy and phosphorylated alpha-synuclein in the skin of E46K-SNCA mutation carriers

    Parkinsonism and Related Disorders, Vol. 65, pp. 139-145

2018

  1. Mitos y evidencias en el empleo de la toxina botulínica: Neurofarmacología y distonías

    Revista de Neurologia, Vol. 66, Núm. 5, pp. 163-172

2012

  1. levodopa en el tratamiento de la enfermedad de parkinson: Mitos y realidades

    Revista de Neurologia, Vol. 55, Núm. 11, pp. 669-688

2011

  1. Can positive family factors be protective against the development of psychosis?

    Psychiatry Research, Vol. 186, Núm. 1, pp. 28-33

  2. Fe de errores de «La guardia específica de neurología en la formación del médico residente en España»

    Neurologia

  3. Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas

    PLoS ONE, Vol. 6, Núm. 10

  4. Multicenter study of brain volume abnormalities in children and adolescent-onset psychosis

    Schizophrenia Bulletin, Vol. 37, Núm. 6, pp. 1270-1280

2010

  1. La guardia específica de Neurología en la formación del médico residente en España

    Neurologia, Vol. 25, Núm. 9, pp. 557-562

2009

  1. Cannabis use in children and adolescents with first episode psychosis: Influence on psychopathology and short-term outcome (CAFEPS study)

    Schizophrenia Research, Vol. 113, Núm. 2-3, pp. 129-137

2008

  1. Antipsychotic treatment in child and adolescent first-episode psychosis: A longitudinal naturalistic approach

    Journal of Child and Adolescent Psychopharmacology, Vol. 18, Núm. 4, pp. 327-336

  2. Association of an EAAT2 polymorphism with higher glutamate concentration in relapsing multiple sclerosis

    Journal of Neuroimmunology, Vol. 195, Núm. 1-2, pp. 194-198

  3. DRD3, but not COMT or DRD2, genotype affects executive functions in healthy and first-episode psychosis adolescents

    American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, Vol. 147, Núm. 6, pp. 873-879

2007

  1. Gene expression profiling of human gliomas reveals differences between GBM and LGA related to energy metabolism and notch signaling pathways

    Journal of Molecular Neuroscience, Vol. 32, Núm. 1, pp. 53-63

  2. The child and adolescent first-episode psychosis study (CAFEPS): Design and baseline results

    Schizophrenia Research, Vol. 91, Núm. 1-3, pp. 226-237

2004

  1. Safety of levetiracetam as adjunctive therapy in epilepsy: The skate trial in Spain

    Revista de Neurologia, Vol. 38, Núm. 12, pp. 1117-1122